Re: AACR 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR 2019

in response to

Re: AACR 2019

narmac

posted on Feb 28, 2019 11:39AM

Narmac,

Will you please provide a link or reference to ZEN-3309 and breast cancer? I don't recall Zenith ever stating that the breast cancer trial would be with ZEN-3309. I think we were told via news release that it would be with ZEN-3694. ZEN-3694 has been shown to synergize with lots of drugs, including PARP inhibitors and enzalutamide. As for CURATE.AI, management stated at AGM that the first patient was free of charge but that the CURATE.AI folks wanted to charge big bucks to apply its use in subsequent patients. That's my recollection. Check the AGM transcript in the link library.